Pandorum Technologies
PrivateLast Round
Series B
Feb 9, 2026
Est. Valuation
$91M
Total Funding Raised
$43.29M
Company Overview
Pandorum Technologies is a biotechnology company founded in 2011 that specializes in tissue engineering and regenerative medicine. The company designs and manufactures 3D functional human tissues, such as bio-engineered corneas and livers, for medical research and therapeutic applications. Its proprietary technology platform utilizes 3D bioprinting, cellular engineering, and biomaterials to develop treatments for conditions like corneal blindness, liver diseases, and lung disorders. Pandorum aims to provide alternatives to animal testing and address the global shortage of organs for transplantation. The company is venture-backed, having raised multiple funding rounds to advance its products to the clinical stage, and has operations in India and the United States.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Advanced Materials
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Pandorum Technologies Comps
Public and private peers based on sector, stage, and business model.
Pandorum Technologies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Feb 9, 2026 | ||||
| Series B | Mar 15, 2024 | ||||
| Series B Extension | Oct 19, 2021 | ||||
| Series B | Sep 6, 2020 | ||||
| Series A | Feb 13, 2018 | ||||
Angel | Dec 24, 2016 |
Pandorum Technologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| IAN Group | Series B |
| 500 Global | Series A |
| 021 Capital | Series B, Series A |
| Kotak Investment Advisors | Series B |
| KITVEN Fund 3 Biotech | Series B |
| Burman Family Holdings | Series B |
| Karnataka Information Technology Venture Fund | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 7, 2026
Partnered with Nucelion to scale exosome manufacturing in the APAC region.
- Oct 1, 2025
Preparing IND-enabling programs for FDA submissions, advancing towards clinical trials.
Pandorum Technologies Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Pandorum Technologies's valuation, stock price, and market status.
